Table 3 Outcome—multivariate analysis.

Variable	OS		LFS		GRFS		RI		NRM
Variable	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Cytogenetic AML classification: Intermediate VS Adverse	1.59 (1.31–1.93)	<0.001	1.62 (1.34–1.96)	<0.001	1.38 (1.15–1.65)	<0.001	2.48 (1.95–3.15)	<0.001	0.79 (0.55–1.12)	0.182
Karnofsky score: > = 90 VS < 90	1.32 (1.09–1.6)	0.004	1.28 (1.07–1.54)	0.007	1.22 (1.03–1.45)	0.023	1.17 (0.91–1.5)	0.22	1.54 (1.16–2.05)	0.003
Type of donors: MSD VS UD 10/10	0.89 (0.73–1.08)	0.249	0.79 (0.65–0.96)	0.014	0.8 (0.67–0.95)	0.013	0.69 (0.54–0.89)	0.004	0.96 (0.71–1.31)	0.796
Age of the Patient at HCT (per 10 years)	1.25 (1.12–1.4)	<0.001	1.15 (1.04–1.29)	0.009	1.09 (0.99–1.2)	0.079	1.03 (0.9–1.18)	0.678	1.39 (1.16–1.67)	<0.001
Female donor to male patient: No VS Yes	1.05 (0.81–1.35)	0.708	1.04 (0.82–1.32)	0.725	1.13 (0.91–1.4)	0.283	1.15 (0.85–1.56)	0.366	0.89 (0.6–1.31)	0.555
RIC or MAC regimen: RIC VS MAC	0.93 (0.76–1.15)	0.516	0.89 (0.73–1.08)	0.242	0.84 (0.7–1.01)	0.07	0.73 (0.55–0.96)	0.023	1.17 (0.86–1.6)	0.317
CMV Donor to patient: Neg to Neg VS Other	0.96 (0.77–1.19)	0.691	0.92 (0.75–1.13)	0.438	0.93 (0.77–1.12)	0.454	0.89 (0.67–1.17)	0.394	0.95 (0.69–1.31)	0.742

Variable	aGVH >=II		aGVH >=III		cGVH		extcGVH		Poly recovery
Variable	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Cytogenetic AML classification: Intermediate VS Adverse	0.91 (0.68–1.22)	0.546	0.83 (0.5–1.38)	0.472	0.72 (0.53–0.98)	0.037	0.58 (0.36–0.94)	0.028	0.85 (0.72–0.99)	0.042
Karnofsky score: > = 90 VS < 90	0.94 (0.72–1.23)	0.659	1.29 (0.83–1.99)	0.259	1.24 (0.96–1.6)	0.1	1.29 (0.89–1.86)	0.179	1.02 (0.87–1.19)	0.812
Type of donors: MSD VS UD 10/10	1.08 (0.82–1.43)	0.59	0.72 (0.46–1.13)	0.152	0.66 (0.51–0.86)	0.002	0.83 (0.57–1.2)	0.321	0.99 (0.85–1.16)	0.93
Age of the Patient at HCT (per 10 years)	0.92 (0.8–1.06)	0.232	0.98 (0.76–1.26)	0.887	0.98 (0.86–1.12)	0.766	0.97 (0.79–1.19)	0.756	0.96 (0.88–1.05)	0.354
Female donor to male patient: No VS Yes	1.17 (0.84–1.64)	0.348	1 (0.56–1.79)	0.999	0.99 (0.73–1.35)	0.967	1.08 (0.7–1.68)	0.724	0.99 (0.82–1.19)	0.89
RIC or MAC regimen: RIC VS MAC	1 (0.76–1.32)	0.994	0.68 (0.41–1.12)	0.127	0.78 (0.59–1.02)	0.074	0.66 (0.44–0.98)	0.042	1.03 (0.87–1.21)	0.764
CMV Donor to patient: Neg to Neg VS Other	0.91 (0.68–1.22)	0.521	0.85 (0.52–1.39)	0.518	0.87 (0.66–1.15)	0.332	1.12 (0.75–1.68)	0.584	1.18 (1–1.39)	0.045

AML acute myeloid leukemia, HR hazard ratio, IQR interquartile range, RI relapse incidence, NRM non-relapse mortality, LFS leukemia-free survival, OS overall survival, aGVH acute graft-versus-host disease, CGVHD chronic graft-versus-host disease, Ext extensive, GRFS GVHD-free and relapse-free survival, CI confidence interval, Poly polymorphonuclear, CMV cytomegalovirus, RIC reduced intensity conditioning, MAC myeloablative conditioning.

Search